Pharmaceutical Excipients E-Book
153,99 €
Mehr erfahren.
- Herausgeber: John Wiley & Sons
- Kategorie: Wissenschaft und neue Technologien
- Sprache: Englisch
This book provides an overview of excipients, their functionalities in pharmaceutical dosage forms, regulation, and selection for pharmaceutical products formulation. It includes development, characterization methodology, applications, and up-to-date advances through the perspectives of excipients developers, users, and regulatory experts. * Covers the sources, characterization, and harmonization of excipients: essential information for optimal excipients selection in pharmaceutical development * Describes the physico-chemical properties and biological effects of excipients * Discusses chemical classes, safety and toxicity, and formulation * Addresses recent efforts in the standardization and harmonization of excipients
Sie lesen das E-Book in den Legimi-Apps auf:
Seitenzahl: 659
Veröffentlichungsjahr: 2016
Ähnliche
Table of Contents
Cover
Title Page
Copyright
List of Contributors
Chapter 1: Excipient Characterization
1.1 Introduction
1.2 Chemical and Physical Properties
1.3 Compendial Characterization Methods and Excipient Performance
1.4 Novel Characterization Techniques
1.5 Excipient Impurities and Implications to Drug Product Stability (Drug–Excipient Interactions)
1.6 Excipient Impurities and their Sources
1.7 Guidance on Excipient Impurity and Interactions
1.8 Analytical Methods for Determining Trace Reactive Excipient Impurities
1.9 Conclusion
References
Chapter 2: Excipients for Conventional Oral Solid Dosage Forms
2.1 Introduction
2.2 Diluents/Fillers
2.3 Binders
2.4 Disintegrants
2.5 Lubricants
2.6 Coating-Related Excipients
2.7 Colorants
2.8 pH Modifiers
2.9 Anticaking Agents
2.10 Antioxidants
2.11 Coprocessed Excipients
2.12 Future Directions
References
Chapter 3: Excipients and their Functionality for Enabling Technologies in Oral Dosage Forms
3.1 Pharmaceutical Excipients
3.2 Solid Dispersions
3.3 Lipid-based Systems
3.4 Nanocrystals
3.5 Oral Modified Release Dosage Forms
3.6 Orodispersible Tablets
3.7 Future Directions
References
Chapter 4: Excipients used in Biotechnology Products
4.1 Unique Challenges in the Formulation Development of Biotechnology Products
4.2 Degradation Pathways of Proteins
4.3 Common Classes of Excipients Used for Biotechnology Products
4.4 Excipients Used in Solid Dosage Forms of Biopharmaceuticals
4.5 Conclusion and Future Outlooks
References
Chapter 5: Excipient Standards and Harmonization
5.1 Introduction
5.2 The Excipient Life Cycle
5.3 Excipient Composition
5.4 Excipient Performance
5.5 Excipient Specifications
5.6 Pharmacopeias and other Compendia
5.7 Harmonization
5.8 The Future
5.9 Conclusion
References
Chapter 6: Regulatory Information for Excipients
6.1 Introduction
6.2 Regulation of Excipients in the United States
6.3 Color Additives and Flavors
6.4 Introduction to IPEC
6.5 Excipient Information for Drug Product Applications
6.6 Drug Master Files
6.7 Supporting Regulatory Information Necessary for Excipients
6.8 New Developments in the United States Affecting Excipients
6.9 Safety Evaluation of Excipients
6.10 The IPEC New Excipient Safety Evaluation Procedure
6.11 Total Excipient Control System
6.12 Excipient Composition: Additives and Processing AIDS
References
Chapter 7: Development of New Excipients
7.1 Introduction
7.2 Development of Novel Excipients
7.3 Development of Coprocessed Excipients
7.4 Development of Modified Excipients
7.5 Summary
References
Chapter 8: PATability of Excipients
8.1 Introduction
8.2 Elucidating Raw Material Variability with Pat Tools
8.3 Pat for Excipients: Case Studies by Unit Operations
8.4 Case Study: Magnesium Stearate Blend Uniformity by NIR
8.5 Conclusion
8.6 Acknowledgments
References
Index
End User License Agreement
Pages
vii
viii
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
329
330
331
332
333
334
335
336
337
338
Guide
Cover
Table of Contents
Begin Reading
List of Illustrations
Chapter 1: Excipient Characterization
Figure 1.1 Classification of USP/NF compendial testing methods specified for excipients. Universal tests cover required testing of ID, assay, and impurities. Specific tests are additional methods to better describe and control excipient chemical and physical properties. Most commonly utilized methods for excipients intended for oral solid formulations are noted in bold text.
Figure 1.2 Harmonization status of general compendial analytical testing methods and excipient monographs. Listing includes the stage of review and publication (1–6) and the agency leading the harmonization process. Status indicated reflects public announcement for July 2013.
Figure 1.3 (a) Initial and (b) aged tablets containing drug substance sensitive to local pH environment provided by a minor excipient (<10 wt%). The aged tablet was exposed to 40 °C and 40% RH for 2 weeks.
Figure 1.4 Chemical imaging of drug product stability showing (a) surface-enhanced Raman chemical imaging of between 0.025% and 0.2% 4-aminophenol (degradant/impurity) versus the pixel position in tablets of acetaminophen and PVP. Images were obtained from plotting the median intensity of the principal band of 4-aminophenol normalized butanethiol peak.
Figure 1.5 FTIR images and histograms of HPMC ibuprofen tablets using blends stored at two RH conditions and compressed at two forces: (a) 60% RH blend compressed at 80 cN m; (b) 80% RH blend compressed at 120 cN m.
Figure 1.6 Dispersion of magnesium stearate (MS) lubricant particles in physical blends analyzed by Raman chemical imaging. Quantification of domain size, number, and localization is provided. Blending time increases from 2 to 60 minutes from the top to bottom tablet images.
Figure 1.7
1
H–
13
C CPMAS solid-state NMR spectra of lactose (a) from different vendors; Kerry-1320016404 (top) and DFE Pharma-42312-7356 [587] (bottom). (b) Zoomed region of Kerry-1320016404 showing five different phases.
Figure 1.8 (a) Low-field NMR analysis of HPMC matrix tablets providing time course images of the darker dry tablet core and lighter gel layer in a static aqueous buffer solution (SEMS,
T
r
= 1800 ms, NS = 2,
T
e
= 6 ms) and (b) corresponding area of the dry tablet core over 8 hours in aqueous media.
Figure 1.9 AFM measurements of dicalcium phosphate dihydrate in contact with aspirin (100) surface (a) image 30 minutes after contact demonstrating pits and new crystalline grown on aspirin surface and (b) and (c) force–displacement curves for low and high RH condition, respectively.
Figure 1.10 Number of documents containing the keyword process analytical technology in pharmacy and engineering journals between 1980 and 2014 in Scopus database. The number of documents per year is indicated in (a) and the top contributing US institutions are listed in (b).
Figure 1.11 Fluid bed drying curves for ibuprofen granulation monitored by in-line NIR measurement of the moisture content.
Figure 1.12 Formaldehyde/formic acid formation from oxidation and breakdown of polyethylene glycol and polysorbates.
Figure 1.13 Chemical interaction between BMS-204352 and formaldehyde.
Figure 1.14 Proposed mechanism of degradation of Irbesartan by formaldehyde.
Figure 1.15 Reaction of haloperidol with HMF to form a condensation product.
Figure 1.16 Piperazine reaction with hydrogen peroxide to form
N
-oxide.
Figure 1.17 Sites susceptible for oxidation.
Figure 1.18 SN2 reaction between API and monochloroacetate impurity.
Figure 1.19 Chemical structure of magnesium stearate and other metallic salts (calcium and zinc) of stearic acids.
Chapter 2: Excipients for Conventional Oral Solid Dosage Forms
Figure 2.1 Crushing strength of tablets of spray-dried lactose samples with varying particle size, compressed at a compaction pressure of 75 MPa and containing 6% water content. From top to bottom () 1–8 µm, (•) 8–16 µm, () 16–24 µm, () 24–32 µm and () 32–45 µm.
Figure 2.2 The effect of moisture content on the tensile strength of binder films. () Gelatin; () methylhydroxyethylcellulose; (•) starch; () acacia; () PVP. The vertical error bar shows limits of error of the means at
P
= 0.95.
Figure 2.3 Volume median diameter of different disintegrants in different media.
Figure 2.4 The impact of tablet aging on the effectiveness of disintegrants on tablet dissolution.
Figure 2.5 PXRD and SEM images of magnesium stearate from three different vendors.
Figure 2.6 Increase in the concentration of
Z
-isomer in uncoated 10 mg potency sorivudine tablets containing no colorant (•); tablets without iron oxide but with 11% w/w coating of Opadry
®
white (o); 0.2% w/w yellow iron oxide () or () 0.2% w/w red iron oxide after 14-day exposure to fluorescent room light (110-ft candle light).
Chapter 3: Excipients and their Functionality for Enabling Technologies in Oral Dosage Forms
Figure 3.1 Classification of solid dispersions.
Figure 3.2 Methods of preparation for SDs.
Figure 3.3 Classification of lipid-based formulations.
Figure 3.4 Classification of modified release dosage form.
Figure 3.5 Classification of matrix MR systems.
Chapter 4: Excipients used in Biotechnology Products
Figure 4.1 Overview of the chemical and physical instability processes observed in biopharmaceuticals and their consequences on the drug product.
Figure Scheme 4.1 Lumry–Eyring framework of protein aggregation.
Figure 4.2 Schematic reaction coordinate diagram of protein aggregation depicted in Scheme 4.1 on an arbitrary free energy scale. Curved lines indicate kinetic energy barriers. Used with permission from Chi et al. [8, 9].
Figure 4.3 The effect of conformational stability on the aggregation rates of (a) recombinant human interferon-g (rhIFN-g) [43, 49] and (b) recombinant human granulocyte colony stimulating factor (rhGCSF) [10]. Increasing the free energy of unfolding (
G
unf
) by the addition of sucrose decreased protein aggregation rates. Used with permission from Chi et al. [8, 9].
Figure 4.4 Possible physical degradation pathways and aggregate forms of proteins caused by interfaces, foreign particulates, and leachables. The Figure shows a vial as an example. These aggregation processes may also occur in other upstream operations and in other containers, closures, and delivery devices. Used with permission from Bee et al. [82].
Figure 4.5 Structures of commonly used nonionic surfactants in biopharmaceutical formulations.
Chapter 5: Excipient Standards and Harmonization
Figure 5.1 Sources of potential excipient components. From Ref. [3]; with permission.
Figure 5.2 The components of a pharmaceutical formulation.
Figure 5.3 Components of pharmaceutical product variability.
Chapter 6: Regulatory Information for Excipients
Figure 6.1 IPEC excipient master file guide format.
Figure 6.2 Level of supporting data needed based on the type of new excipient.
Figure 6.3 Three main areas of control within the total excipient control system.
Chapter 7: Development of New Excipients
Figure 7.1 Development chart of new excipients.
Figure 7.2 Development organization and structure.
Figure 7.3 Steps and milestones in product development.
Figure 7.4 Monomers and polymerization techniques.
Figure 7.5 Optimization helix.
Figure 7.6 Analytical characterization of a new excipient.
Figure 7.7 Toxicological studies required for pharmaceutical excipients for oral applications.
Figure 7.8 Relationship between excipient supplier, pharmaceutical company, and health authority.
Figure 7.9 Synthesis of Kollicoat IR.
Figure 7.10 Structure of Kollicoat IR.
Figure 7.11 Comparison of most relevant properties of immediate release coatings: Kollicoat IR versus market standard.
Figure 7.12 LCCC–SEC analysis of Kollicoat IR.
Figure 7.13 Regulatory aspects of Kollicoat IR.
Figure 7.14 Particle structure of Ludiflash (SEM photo).
Figure 7.15 Hardness–disintegration time–compression force profile of Ludiflash (comparison of different tablet presses).
Figure 7.16 Relationship between volume and projected area of spheres.
Figure 7.17 Impact of particle size on binding properties.
Figure 7.18 SEM photos of Kollidon VA 64 Fine.
Figure 7.19 Hardness–compression force profile of vitamin C tablets.
Chapter 8: PATability of Excipients
Figure 8.1 NIR spectra of L-(+) lactic acid (1), stearic acid (2), hydroxypropyl cellulose LF (3), crospovidone NF (4) and magnesium stearate (5).
Figure 8.2 NIR spectra of MCC PH 102 (1), lactose anhydrous DC NF (2), sodium starch glycolate (3) and sodium citrate dihydrate FCC USP (4).
Figure 8.3 Raman spectra of corn starch (1), lactose monohydrate (2), xylitol (3) and magnesium stearate (4).
Figure 8.4 Raman spectra of crospovidone (1), MCC PH 102 (2), MCC PH 200 (3), MCC PH 101 (4) and croscarmellose sodium (5).
Figure 8.5 NIR spectra of calibration blends during fluid bed drying showing the main absorption bands at 1470–1408 nm and 1960–1890 nm.
Figure 8.6 % w/w water versus time for three different batches of a wet granulated product and LOD reference values.
Figure 8.7 (a) Representative preprocessed calibration spectra covering the range for the model generation (b) Calibration curve showing the regression of % w/w magnesium stearate values (gravimetric weight) to the NIR-predicted values.
Figure 8.8 Typical blending profile of magnesium stearate in PB (: Batch 1, : Batch 2) and FB (: Batch 1, : Batch 2).
Figure 8.9 %RSD vs. time for magnesium stearate in PB (: Batch 1, : Batch 2) and FB (: Batch 1, : Batch 2).
Figure 8.10 NIR spectrum of FB (1) pure magnesium stearate (2), and lump found in FB (3).
List of Tables
Chapter 1: Excipient Characterization
Table 1.1 Examples of Excipients with Indication of Chemical Classification, Key Common Compendia Tests, and Other Specific Tests That Can Be Utilized by Manufacturers and Formulation Scientists
Table 1.2 Revised Default Concentration Limits for Heavy Metal Impurities in Excipients and Drug Substances in Monograph <232>
Table 1.3 Molar Phase Composition of Lactose Batches from Vendors Kerry and DFE Pharma
Table 1.4 A Sample of Drug Incompatibility with Excipient Impurities
Table 1.5 Reported Trace Organic Acids Impurities in Pharmaceutical Excipients
Table 1.6 Profiling of Reactive Impurities in Selected Lots of Pharmaceutical Excipients
Chapter 2: Excipients for Conventional Oral Solid Dosage Forms
Table 2.1 Properties of Various Klucel-EF and HPC-L Lots Sourced from Hercules and Nippon Soda
Table 2.2 Functionality-Related Characteristics of a Binder That Could Impact the Manufacturing and Performance of an Oral Solid Dosage Form
Table 2.3 Functionality-Related Characteristics of Disintegrants and Their Potential Impact in an Oral Solid Dosage Form
Table 2.4 Functionality-Related Characteristics of Magnesium Stearate That Could Impact the Manufacturing and Performance of an Oral Solid Dosage Form
Table 2.5 Dissolution of 40 mg Potency Capsules Hand Filled with Granules Containing 1% w/w Magnesium Stearate at Various Time Points During Capsule Filling Showing Impact of Overmixing
Table 2.6 Details of Marketed Coprocessed Excipients and Their Claimed Benefits
Chapter 3: Excipients and their Functionality for Enabling Technologies in Oral Dosage Forms
Table 3.1 Examples of FRCs and Their Testing Methods [3]
Table 3.2 Excipients Used in SDs [17]
Table 3.3 FRCs and FRTs of Excipients Used in SDs
Table 3.4 Excipients Used in LBFs
Table 3.5 FRCs and FRTs for Excipients Used in LBFs
Table 3.6 Methods of Preparation of Nanocrystals
Table 3.7 List of Stabilizers Used for Nanocrystals
Table 3.8 FRCs and FRTs of Excipients Used
Table 3.9 Excipients Used in MR Systems
Table 3.10 Excipients Used in Hydrophobic Matrices
Table 3.11 Excipients Used in Lipid Matrices [17, 44]
Table 3.12 FRCs and FRTs of Polymers Used in Hydrophilic Matrix Systems [3, 40, 49, 50]
Table 3.13 Osmotic Agents Used in Osmotic Pumps [17, 52]
Table 3.14 FRCs and FRTs of Semipermeable Membranes Used in Osmotic Pumps [17, 52]
Table 3.15 Excipients Used as Wicking Agents [17, 53]
Table 3.16 Excipients Used as Pore Formers [17, 52]
Table 3.17 Excipients Used as Flux Regulators [17, 53]
Table 3.18 Excipients Used as Plasticizers [17, 53]
Table 3.19 FRCs and FRTs of Excipients Used in Osmotic Pumps [3]
Table 3.20 Comparison of Multiparticulate Systems with Single-Unit Dosage Forms [58]
Table 3.21 Excipients Used in ODTs [17]
Table 3.22 FRCs and FRTs of Excipients Used in ODTs [65]
Chapter 4: Excipients used in Biotechnology Products
Table 4.1 Factors that Influence Protein Adsorption to Surfaces and Interfaces
Table 4.2 Summary of Excipients Used in Biopharmaceutical Formulations and Their Effects
Table 4.3 Common Excipients Used in Lyophilized Biopharmaceutical Products
Chapter 5: Excipient Standards and Harmonization
Table 5.1 The “Tally” of Known Deaths Due to Ethylene Glycol/Diethylene Glycol Either Being Used in or Determined to Be an Adulterant of Medicines for Human Use
Table 5.2 ICH Guidelines Relevant to Pharmaceutical Excipients
Table 5.3 Excipients Included in the PDG Harmonization Process (as of June 06, 2012)
Table 5.4
Table 5.5 The PDG Harmonization Process [19]
Chapter 6: Regulatory Information for Excipients
Table 6.1 Section P.4 of the CTD, Control of Excipients
Table 6.2 ICH Testing Guidance
Table 6.3 List of IPEC Guidelines and White Papers
Chapter 7: Development of New Excipients
Table 7.1 Main Categories and Examples of New Excipients
Table 7.2 Types of Excipient Developments
Table 7.3 Content of a Type IV Drug Master File and of Proposed Content for a “Regulatory Information File”
Table 7.4 Development of Coprocessed Excipients
Table 7.5 Particle Characteristics of Ludiflash
Chapter 8: PATability of Excipients
Table 8.1 NIR PAT Tools and Conditions Used to Monitor Pharmaceutical Excipients in Blends
Table 8.2 NIR PAT Tools and Conditions to Monitor in Tablets
Table 8.3 NIR Instrument Parameters
Table 8.4 NIR Method Validation Parameters and Results
Pharmaceutical Excipients
Properties, Functionality, and Applications in Research and Industry
Edited by
Otilia M. Y. Koo
Copyright © 2017 by John Wiley & Sons, Inc. All rights reserved
Published by John Wiley & Sons, Inc., Hoboken, New Jersey
Published simultaneously in Canada
No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permissions.
Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.
For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.
Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.
Library of Congress Cataloging-in-Publication Data:
Names: Koo, Otilia M. Y. (Otilia May Yue), 1974- editor.
Title: Pharmaceutical excipients : properties, functionality, and applications in research and industry / edited by Otilia M Y Koo.
Description: Hoboken, New Jersey : John Wiley & Sons, Inc., [2017] | Includes bibliographical references and index.
Identifiers: LCCN 2016022475| ISBN 9781118145647 (cloth) | ISBN 9781118992418 (PDF) | ISBN 9781118992425 (ePub)
Subjects: | MESH: Excipients | Dosage Forms | Technology, Pharmaceutical–methods
Classification: LCC RS201.E87 | NLM QV 800 | DDC 615.1/9–dc23 LC record available at https://lccn.loc.gov/2016022475
List of Contributors
Arvind Kumar Bansal
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Punjab, India
Eva Y. Chi
Department of Chemical and Biological Engineering and Center for Biomedical Engineering, University of New Mexico, Albuquerque, NM, USA
Claudia Corredor
Pharmaceutical Development, Bristol-Myers Squibb Company, New Brunswick, NJ, USA
Christopher C. DeMerlis
Global Regulatory Affairs, Colorcon, Inc., West Point, PA, USA
Divyakant Desai
Drug Product Science and Technology, Bristol-Myers Squibb Company, New Brunswick, NJ, USA
David Good
Drug Product Science and Technology, Bristol-Myers Squibb Company, New Jersey, USA
Felicitas Guth
BASF SE, Global Research & Formulation Nutrition & Health, Ludwigshafen, Germany
Umesh Kestur
Drug Product Science and Technology, Bristol-Myers Squibb Company, New Brunswick, NJ, USA
Sakshi Khurana
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Punjab, India
Karl Kolter
BASF SE, Global Research & Formulation Nutrition & Health, Ludwigshafen, Germany
R. Christian Moreton
FinnBrit Consulting, Waltham, MA, USA
David R. Schoneker
Global Regulatory Affairs, Colorcon, Inc., West Point, PA, USA
Kunnal Sharma
Department of Pharmaceutical Technology (Formulations), National Institute of Pharmaceutical Education and Research (NIPER), Punjab, India
Alexa Smith
Global Regulatory Affairs, Colorcon, Inc., West Point, PA, USA
Shreya Thakkar
Department of Pharmaceutical Technology (Formulations), National Institute of Pharmaceutical Education and Research (NIPER), Punjab, India
Yongmei Wu
Drug Product Science and Technology, Bristol-Myers Squibb Company, New Jersey, USA
Chapter 1Excipient Characterization
David Good and Yongmei Wu
Drug Product Science and Technology, Bristol-Myers Squibb Company, New Jersey, USA
1.1 Introduction
A comprehensive understanding of the chemical and physical properties of common pharmaceutical excipients is essential to the design of high-quality drug products that provide consistent performance. In many pharmaceutical formulations, the drug substance can be susceptible to chemical and physical changes induced by the properties of the bulk excipients [1]. This is often more pronounced for drug products where the ratio of excipient content to drug is very high (i.e., low drug loading formulations). In recent years, the regular advancement of highly potent and selective drug candidates has led to more formulations that are predominately comprised of excipients and incorporate lower levels of the active pharmaceutical ingredient (API). In addition, potent drug candidates often exhibit low aqueous solubility and can require enabling formulation technologies, which include unique excipients and/or processing steps, to provide the desired clinical exposure at some stage during the clinical development program [2]. These trends in drug substance properties as well as the implementation of quality by design (QbD) product development strategies place an increased emphasis on detailed characterization of excipients to achieve robust formulations and processes.
This chapter focuses on a fundamental description of the chemical and physical properties of excipients, the associated characterization methods, and implications for formulation and processing of drug products. Numerous publications such as USP monographs provide an introduction to basic compendial excipient test methods and properties. These compendial descriptions and methodologies serve the basis for classification and release testing of materials; however, additional characterization is often required in the selection and processing of excipients. The content presented in this chapter provides the reader an introduction to the current methodologies and excipient properties that are most significant for the development of a commercial drug product. Included in this chapter are detailed descriptions of excipient stability and impurities as well as material variability that can influence drug product performance. These considerations are essential to the successful preparation of dosage forms for preclinical and clinical development programs. As such, this material is valuable to all scientists and students involved in pharmaceutical research from the discovery to commercial formulation and manufacture stages.
1.2 Chemical and Physical Properties
There is extensive diversity in the chemical structural elements and physical properties of pharmaceutical excipients. Excipients can be categorized in common chemical classifications including inorganics (e.g., iron oxide as pigments, calcium phosphate as filler), small molecule organics and their salts (e.g., mannitol diluent/sweetener, sodium citrate alkalizing agent), as well as polymeric excipients that can be fully synthetic or naturally derived (e.g., hypromellose, starch). The diversity is further expanded by an abundance of natural product derivatives where feedstock variability (raw materials), isolation, and chemical processing can impact the purity and structural attributes. Table 1.1 provides an overview of several common functional and chemical classifications of excipients with USP monographs. In total, there are 230 excipient monographs available to formulators with published monographs in the Handbook of Pharmaceutical Excipients. Each monograph can represent numerous material grades (i.e., polymer molecular weight, degree of substitution, particle size distribution, morphology) and be available from multiple manufacturers. Alternate manufacturers often employ different synthetic schemes or isolation techniques that can result in slight differences in physical properties (i.e., melt temperature, crystallinity, loss on drying, particle size) and chemical profile (i.e., trace impurities). The methods of manufacture of excipients are often proprietary trade secrets and therefore it is incumbent on formulators to identify essential material property profiles of key excipients, which is reviewed later in this chapter. To generate this knowledge formulation scientists rely on numerous compendial excipient characterization methods and develop novel methods to analyze key quality materials attributes of a formulation.
Table 1.1 Examples of Excipients with Indication of Chemical Classification, Key Common Compendia Tests, and Other Specific Tests That Can Be Utilized by Manufacturers and Formulation Scientists
Organic (Synthetic,
Natural
)
Key Characterization Methods
Excipient function
Inorganic
Small molecule
Polymeric
Compendial (
Figure 1.1
)
Others
Diluent
CaHPO
4
Lactose,
mannitol
Starch, cellulose (powdered or microcrystalline)
PSD: <429> LDS, sieving <786>, density, bulk, tap, true <616, 699>; <616>crystallinity;<731> LOD; water content <921>; SSA <846>; flow <1174>;Particle shapeParticle size distribution <429>Surface areaThermal propertiesPolymorphic formCrystallinity <616>Amorphous content
Water activity, GPC, XRD, ssNMR, SEM, AFM, TEM, FBRM,
Binder
CaCO
3
Dextrates, maltitol
Copovidone, hydroxypropyl cellulose
Disintegrant
Magnesium aluminum silicate
–
Crospovidone, sodium starch glycolate, croscarmellose sodium, polacrilin potassium
Lubricant
Talc
Magnesium stearate, sodium stearyl fumarate, stearic acid
–
Glidant
SiO
2
colloidal, MgO,
talc
–
–
Colorant
Iron oxides, TiO
2
Tartrazine, sunset yellow FCF indigo carmine, etc.
–
Coating and film-forming agents
ZnO
Sucrose
Cellulose acetate phthalate, polyvinyl acetate phthalate, polyethylene oxide, hypromellose, polyvinyl alcohol, etc.
Film strength and adhesion
Plasticizer
–
α
-Tocopherol,
butyl stearate, benzyl benzoate, etc.
Propylene glycol, polyethylene glycol
911, 881, 891
Rheology, thermal mechanical analysis (TMA)
Flavor/sweetening/fragrance
–
Vanillin, menthol, fructose, ethyl lactate, monosodium glutamate, etc.
–
Electronic tongue
Antioxidant
α
-Tocopherol
, butylated hydroxytoluene (BHT), ascorbic acid
–
UV HIL exposure
Source: Rowe [3]. Reproduced with permission of RPS Publishing.
Together these USP general chapters on test methods (Figure 1.1) cover elements of the chemical and physical properties at the molecular level (e.g., NMR, IR, NIR, and UV spectrophotometry) as well as that of particulates (e.g., distribution of particle sizes, optical microscopy) and bulk material (e.g., viscosity, loss on drying, thermal analysis). While these monographs and methods provide the core testing protocols for routine certification of materials for release specifications, certificate of analysis, and compendial compliance, it is routine for manufacturers and formulation scientists to conduct extensive supplemental testing to ensure the quality and consistency of excipient properties. While it is of great interest to formulators to conduct additional noncompendial functional testing regarding the distinct critical material properties of a developmental product, there is routine attention given to the core information recorded in compendial tests. This is exemplified by publications that demonstrate the compilation and statistical analysis of reported CoA data to identify material properties that are unique to a manufacture location or period of time [4]. This type of analysis is commonly pursued by quality groups that track results of certified testing and can be valuable to formulators seeking to identify critical quality attributes by incorporating excipient lots that most represent the material diversity in the early screening and development stages. In addition, the Excipient Consortium (NIPTE – Advanced Pharmaceutical Materials Knowledge Center) and other similar groups provide extensive testing and make data and materials available to membership composed of universities, manufacturers and pharmaceutical companies. Searchable databases of material records and supplemental functional testing (e.g., shear cell and compaction testing) greatly improve the ability of formulators to project potential variability to critical material attributes and design robust formulations to accommodate the typical range of material properties.
Figure 1.1 Classification of USP/NF compendial testing methods specified for excipients. Universal tests cover required testing of ID, assay, and impurities. Specific tests are additional methods to better describe and control excipient chemical and physical properties. Most commonly utilized methods for excipients intended for oral solid formulations are noted in bold text.
Further expansion of the library of pharmaceutical excipients to include new chemical entities is a challenging endeavor with regulatory requirements that involve significant investment and time [5]. These requirements include extensive safety and toxicology studies for the introduction of new excipient chemistries and create an incentive to develop unique innovative physical material properties from the existing library of chemicals. Materials are often engineered to meet compendia specifications for existing excipient monographs; however, they often employ unique processing methods or combinations of primary excipients (coprocessing) to provide innovative properties and eliminate or lessen the regulatory burden for acceptance.
1.3 Compendial Characterization Methods and Excipient Performance
Compendial test methods contained in detailed pharmacopeia monographs are readily available to formulation scientists. These monographs serve the basis for core techniques in chemical and physical analyses to identify excipients and to ensure quality through routine analysis. Quality specifications regarding the purity and stability of excipients rely on these compendial test methods (Figure 1.1). USP/NF monographs contain both general tests and specific tests that are applied to characterize excipients. USP/NF monographs are stability indicating and contain a suitable assay method or an accompanying procedure to identify impurities that can demonstrate stability.
Common elements of excipient monographs include name and description, identification test, assay and impurities method(s), packaging and storage conditions as well as any specific tests needed to better describe and control an excipient (e.g. microbial limit test, pH, etc.). The functionality of excipients are mostly dictated by an individual formulation (i.e., formulation quality attribute) and the processing technologies utilized to manufacture a dosage form. Therefore, incorporation of functional tests and acceptance criteria are limited in monographs to cases where routine test are not sufficient to support the majority applications for a material.
1.3.1 Pharmacopoeial Harmonization
Excipients that have established worldwide acceptance in compendial testing and specification are given considerable preference as they could be universally integrated into a drug product. This universal compendial designation greatly simplifies the ability to demonstrate quality and equivalence of a formulation filed with numerous regulatory health authorities. Efforts on global harmonization of the international pharmacopeia landscape (United States Pharmacopeia–National Formulary (USP/NF), EP, Japanese Pharmacopoeia (JP)) have sought to enact standards that enable consistent quality of excipients and minimize the need for regional test methods and repeat testing, therefore facilitating drug products to be rapidly introduced to international markets. Harmonization of general chapters including analytical methods as well as excipient monographs is coordinated by one pharmacopeia (USP, EP, or JP) during a staged working procedure by a Pharmacopeial Discussion Group (PDG). There are six stages to reach a harmonized monograph, which include identification, investigation, expert committee review, official inquiry, consensus, and implementation. A listing of harmonization activity for excipients and analytical methods is included in Figure 1.2, which demonstrates a majority of monographs identified for harmonization have reached the implementation stage. The PDG reports 58% of excipients at stage six as of July 2013. Similarly, the majority of general chapters related to characterization methods have reached completion of stage six harmonization status.
Figure 1.2 Harmonization status of general compendial analytical testing methods and excipient monographs. Listing includes the stage of review and publication (1–6) and the agency leading the harmonization process. Status indicated reflects public announcement for July 2013.
1.3.2 Monograph Revisions
USP–NF monographs are subject to routine review and the USP provides guidance for revisions to allow for changes to testing methods and excipient specifications. A recent example of interest is the revision of the monograph for characterization of heavy metals <231>, which has been replaced by elemental limits <232> and test procedure <233>. Under monograph <231> it is incumbent on excipient manufacturers to certify the control of inorganic materials of potential harm are below toxic levels. In addition, it is the responsibility of excipient users to substantiate the absence of impurities before incorporating into drug products.
A wet chemistry colorimetric test method specified in <231> has been in routine use for decades; however, this test relies on subjective visual inspection for precipitation of metal sulfides. A colored precipitate of sulfide-forming elements is visually compared to a 10 ppm Pb standard to determine compliance with the heavy metal limit. Resolution of individual elements is not viable with USP <231>. Experiences with <231> have demonstrated poor resolution and quantification that has resulted in lower than actual amounts for numerous heavy metals known to be toxic (lead, arsenic, mercury, and cadmium). In particular, the required 600 °C ignition temperature prevents the <231> method from resolving mercury and other volatile analytes. The revisions incorporated in <232> account for a wider range of metals with potential to impact quality and define individual limits according to known toxicity (Table 1.2). Included in the new limits are catalysts that were not previously able to be resolved. Multielement ICP-MS and ICP-OES techniques have been established in <233> to simultaneously detect a great number of metals of interest with high specificity and sensitivity. Of particular interest to the stability of drug products is the high resolution of copper, which is often linked to the catalysis of oxidative reaction in drug products. However, identification of speciation (oxidation state), which is important in reactivity of the metal impurity with other formulation components, is not covered by the new testing. Toxicity associated with the defined limits assumes that the entire amount of metal recorded is present in the oxidation state that demonstrated the greatest toxicity.
Table 1.2 Revised Default Concentration Limits for Heavy Metal Impurities in Excipients and Drug Substances in Monograph <232>
Concentration Limits (µg/g)
Element
Oral Drug Products Maximum Daily Dose of ≤ 10 g/day
Parenteral Drug Products Maximum Daily Dose of ≤ 10 g/day
Inhalational Drug Products Maximum Daily Dose of ≤ 10 g/day
Cadmium
2.5
0.25
0.15
Lead
0.5
0.5
0.5
Inorganic arsenic
0.15
0.15
0.15
Inorganic mercury
1.5
0.15
0.15
Iridium
10
1.0
0.15
Osmium
10
1.0
0.15
Palladium
10
1.0
0.15
Platinum
10
1.0
0.15
Rhodium
10
1.0
0.15
Ruthenium
10
1.0
0.15
Chromium
–
–
2.5
Molybdenum
10
1.0
1.0
Nickel
50
5.0
0.15
Vanadium
10
1.0
3.0
Copper
100
10
10
In addition to toxicity, the numerous heavy metals present at these controlled levels can catalyze reactions with drug substance and negatively impact the stability and impurity profile.
The combined experiences of excipient manufacturers and end users as well as the evolution of analytical technologies are considered when revisions are proposed to existing monographs. Typical justification for revision includes public safety and health reasons, insufficient supply of pharmacopoeial quality material, poor availability of specified reagents, new reagents or methods of preparation, and advances to analytical procedures (more appropriate, accurate, or precise). Additional monographs proposed for revision in 2013 include <41> balances, <659> packaging and storage requirements, high fructose corn syrup, and <1092> dissolution procedure: development and validation.
1.4 Novel Characterization Techniques
The critical material properties of excipients are unique to every drug formulation. These properties are impacted by the chemical and physical nature of the drug substance as well as other excipients, required route of administration dosage form, formulation processing methods, and the intended storage and handling of the final product or intermediates. Critical material properties defined by the needs of a particular formulation are typically not entirely elucidated by the common characterization techniques described in USP/NF monographs.
Analytical testing in monographs cover many techniques suitable for routine materials characterization; however, formulation scientists frequently need to employ specialized equipment and methods that are tailored to needs for identifying specific issues related to the performance and quality of a particular formulation. It is important to note that monographs and associated tests or specification ranges for a particular excipient are not suitable to indicate exact equivalence in performance or composition. Typically, a significant variety of material properties exist for a group of excipients that all meet a common compendia standard. A pharmaceutical scientist needs to understand material differences of excipients with identical compendial classification and identify where there could be potential to influence drug product performance or quality.
Examples provided in this section serve to demonstrate novel excipient characterization methods that are created by pharmaceutical scientists to develop high-quality robust processing and performance attributes of new formulations. These few contributions demonstrate how material properties and variability (lot–lot or manufacturer) can be identified and related to formulation performance and process development.
1.4.1 Chemical Imaging
Application of chemical imaging throughout the drug product manufacture process enables more comprehensive identification and understanding of critical material attributes by resolving how excipients respond to applied process conditions (compaction, milling, temperature, moisture, etc.) and affect downstream performance properties (disintegration/dissolution, tablet hardness, chemical stability, etc.). Raman, FTIR, NIR, and other chemical imaging methods are strong examples of specific functional testing of excipients and their interaction(s) with other formulation additives to identify key material attributes. These methods often require extensive development to tune resolution and sensitivity to the materials of interest and to apply for measurement of drug products or various drug product intermediates. In addition, these techniques are typically paired with a chemometric processing tool such as partial least squares (PLS), principal component analysis (PCA), multivariate curve regression (MCR), or other suitable means to treat and analyze the acquired data. Often, the complete variability of excipients cannot be fully anticipated and this provides challenges to calibrating methods and extrapolating data outside prior experiences [6]. However, a working method can still provide mechanistic insight into the attributes of functional excipients and aid in the design of robust drug product processes and selection of high-quality materials.
Basic IR spectroscopy is described in general compendial test methods, but advances in the application of NIR methods for release testing of tablet potency and uniformity have recently been demonstrated in regulatory documents and the pharmaceutical literature [7]. This type of characterization method is product specific and requires extensive method development and validation. The value for developing these novel techniques is the ability to have rapid and extensive testing of tablets that can better track the robustness of a formulation and process. NIR chemical imaging (NIR-CI) techniques, which are often applied to API for potency and uniformity determination, can also readily be employed to track excipient performance in a dosage form. The analysis of functional excipients (disintegrants, binders, lubricants, etc.) can be performed with numerous commercially available NIR-imaging systems capable of spatial and chemical resolution for analysis of intact tablets or drug product intermediates. NIR can determine content uniformity, moisture content, particle size/distribution of all the sample components, contaminants, as well as polymorph distributions (e.g., lactose α vs β) [7a, 8]. A powerful example of the utility of combined chemical and spatial information is the ability to localize the drug substance degradation products and overlay information regarding the excipient composition and moisture of the immediate region to elucidate drug product degradation mechanisms and the impact of specific formulation components.
The localization of excipients in drug products or intermediates can be important to specific performance or quality attributes including the chemical stability of the drug substance. One example is the routine use of excipients as pH modifiers that alter the solubility and dissolution rate of ionizable pharmaceutical compounds through influence of the local pH. If chemical stability of the drug substance is also sensitive to pH, the formation of impurities can be accelerated by additives intended to impact solubility and dissolution. Figure 1.3 shows a tablet that was stored at accelerated stability condition (40 °C and 40%RH) with an overall dark color and distinct localized spots. Raman and IR imaging confirmed the visual intensity of spots was related to regions that were rich with particles of API and the acidic modifying excipient. In cases where impurities from the excipient or drug substance that form during storage do not present a vivid color, the localization of components can be facilitated by chemical imaging techniques (Raman, NIR, FTIR, etc.). Figure 1.4a demonstrates one case from the literature where surface-enhanced Raman chemical imaging localized a degradation product of acetaminophen in tablets containing PVP as excipient [9]. Similar work has looked at furosemide tablets chemical degradation using NIR imaging and a PLS model generated from pure component data spectral to derive the contribution and distribution of excipients, drug substance, and degradation products [10]. The utility of NIR imaging analysis has also been demonstrated for a BMS developmental prodrug compound to understand mechanisms that lead to the formation of parent drug in tablets as shown in Figure 1.4b. These types of localized degradants can often be difficult to detect in mean spectrum from the bulk samples; however, NIR or Raman chemical imaging provides high-resolution spatial data that improves the detection of localized minor components. Chemical imaging allows rapid acquisition and analysis of trace materials resulting from excipients and their interactions in drug products, which in turn provides improved fundamental understanding of mechanisms and degradants to support the design of high-quality products.
Figure 1.3 (a) Initial and (b) aged tablets containing drug substance sensitive to local pH environment provided by a minor excipient (<10 wt%). The aged tablet was exposed to 40 °C and 40% RH for 2 weeks.
Figure 1.4 Chemical imaging of drug product stability showing (a) surface-enhanced Raman chemical imaging of between 0.025% and 0.2% 4-aminophenol (degradant/impurity) versus the pixel position in tablets of acetaminophen and PVP. Images were obtained from plotting the median intensity of the principal band of 4-aminophenol normalized butanethiol peak.
Source: De Bleye [9]. Reproduced with permission of Elsevier. (b) Identification of prodrug (top) to parent (bottom) conversion in a prototype BMS tablet formulation. Images and data courtesy of Boyong Wan and Christopher Levins (Bristol-Myers Squibb, 2015).
The interaction of excipients and formulations with moisture can go beyond impacting chemical stability to induce changes in physical properties and response to common processing conditions. In situ chemical imaging has demonstrated utility to determine the densification behavior of excipient and drug mixtures exposed to different environmental conditions and stresses [11]. Figure 1.5 shows FTIR images with HPMC absorbance bands from mixtures with ibuprofen under two compaction pressures and relative humidity conditions. It is clear from the images and associated histograms that greater densification (dark pixels) is achieved from higher moisture content and compaction force. This technique enables the developers to study the impact of moisture on multiple components during compaction process and the potential to tailor composition and conditions to provide robust tablet processing and performance. The same group has also demonstrated complementary use of X-ray microtomography techniques, which provide greater penetration of tablet samples compared to in situ FTIR images that are restricted to resolving surface attributes [12].
Figure 1.5 FTIR images and histograms of HPMC ibuprofen tablets using blends stored at two RH conditions and compressed at two forces: (a) 60% RH blend compressed at 80 cN m; (b) 80% RH blend compressed at 120 cN m.
Source: Elkhider [11]. Reproduced with permission of Elsevier.
The distribution of magnesium stearate lubricant is often critical to the processing attributes as it alleviates sticking of powder/compacts to machine surfaces. In addition, downstream performance characteristics, including dissolution/disintegration behavior of the dosage form, can be influenced by the physical and chemical characteristics of magnesium stearate such as particle size and morphology as well as ratio of stearic to palmitic content. The dispersion of magnesium stearate in powder blends is of specific interest to formulators since these materials are intended for activity at the interface between particles and the surfaces of processing equipment. The resolution of magnesium stearate dispersion is not readily elucidated by any specified compendial testing methods and requires unique instruments and methods.
Raman mapping is one chemical imaging technique which has been used to quantify the blendability of a lubricant. Raman analysis has been applied to increase processability and determine the appropriate blend time and level of shear. Additionally, Raman imaging data can be correlated to the wetting or dissolution of dosage forms where negative performance has been demonstrated if a lubricant provides too much coverage of particle surfaces (from either overblending or amount of lubricant). This can also be applied when changing equipment and on scale-up. Figure 1.6 demonstrates the localization of magnesium stearate with regard to the surface of a tablet comprised mostly of API and other excipient particles [13]. Lubricant particles are bright intensity areas, while the API and other excipients are represented in lower intensity (dark/black). Samples representing prolonged mixing time (lower panels of Figure 1.6) exhibited less pixels/domains associated with high (>15%) lubricant concentration and a greater number of domains with low (∼1–4%) lubricant concentrations. High lubricant concentration domains are associated with aggregated lubricant particles. When concentrated lubricant domains are broken, a greater abundance of low lubricant concentration domains are formed, which is consistent with more uniformly distributed lubricant particles. The images in Figure 1.6 suggest that extended bin blending or larger scale blending operations that increase total shear can improve lubricant uniformity on the surface of tablets. This example demonstrated the potential to resolve excipients and analyze interactions with material properties (surface area, particle size, etc.) and process conditions (blend time, scale, speed, etc.). This type of technique complements bulk analysis and downstream process evaluation of blend performance (tabletability, hardness, friability, segregation, uniformity, etc.) and provides insights that can save time and material through detailed characterization of small blends in early stages of formulation or process development.
Figure 1.6 Dispersion of magnesium stearate (MS) lubricant particles in physical blends analyzed by Raman chemical imaging. Quantification of domain size, number, and localization is provided. Blending time increases from 2 to 60 minutes from the top to bottom tablet images.
Source: Lakio [13]. Reproduced with permission of Springer.
1.4.2 Advanced NMR Techniques
The increased availability and use of solid-state NMR (ssNMR) is one example where advanced analytical techniques facilitate a greater fundamental understanding of excipient properties that can impact formulation. Drug product formulations must consider and account for the variability of excipient properties that are in many cases attributed to proprietary sourcing and production methods of multiple vendors. To ensure uninterrupted supply of medicine to patients, the qualification of multiple excipient sources for a drug product is routinely sought. The equivalence of excipient performance from multiple vendors has to be determined by the formulation scientists. The application of ssNMR makes it possible to identify many unique characteristics of some excipients that could be associated with a specific manufacturing processes or the material supply chain. If differences in chemical or physical properties exist for a critical excipient, suitable analytical methods and controls must be established to maintain product quality.
ssNMR was recently used to study structural characteristics of lactose acquired from multiple vendors. In Figure 1.7a, the carbon-13 NMR spectrum of lactose as received from two vendors demonstrates numerous structural differences that are evident from unique chemical shift peaks. The resolution and assignment of multiple physical phases (polymorphs, amorphous, hydrated) was achieved from a detailed analysis of the spectrum as shown for Kerry sourced lactose in Figure 1.7b. Lactose is a commonly used filler/diluent available from multiple large vendors in numerous grades and each of these materials comprises of a complex mixture of multiple phases as resolved by ssNMR. The relative quantitative phase compositions of lactose from vendors in Figure 1.7a ssNMR are listed in Table 1.3. The largest differences in phase content are for α-anhydrous lactose (0–13%) and β lactose (50–75%). These differences in lactose phase composition have the potential to impact processing, stability, and performance of a drug product. For example, the compactability of tablets with different lactose polymorphs has been demonstrated as well as the sensitivity of certain drug substances to the transfer of moisture from excipients [14]. Similarly, examples of ssNMR have shown resolution of bulk lactose polymorphs and amorphous phases from common processing techniques such as spray drying of aqueous suspensions. Other reports have shown a high degree of structural similarity across numerous microcrystalline cellulose (MCC) grades from a single supplier [15]. Specialized techniques such as ssNMR can provide fundamental data to support the design of robust high-quality formulations and processes when considering the selection, substitution, or processing of excipient grades from numerous suppliers.
Figure 1.71H–13C CPMAS solid-state NMR spectra of lactose (a) from different vendors; Kerry-1320016404 (top) and DFE Pharma-42312-7356 [587] (bottom). (b) Zoomed region of Kerry-1320016404 showing five different phases.
Figure courtesy of Anuji Abraham and George Crull (Bristol-Myers Squibb, 2014).
Table 1.3 Molar Phase Composition of Lactose Batches from Vendors Kerry and DFE Pharma
Vendor Name
Kerry
DFE
Lactose batch no
1320016404
42312-7356(587)
Molar composition
%
%
α-Lactose, H
2
O
5
0
β-Lactose
50
75
α-Lactose anhydrous
13
0
Unknown
25
19
Amorphous
7
5.4
Source: Bristol-Myers Squibb, 2014. Reproduced with permission of Bristol-Myers Squibb Company.
Phase composition was determined by calculating the area under the peaks (of anomeric carbon atoms) of 1H–13C CPMAS NMR spectra after deconvolution of the spectra using ACD (version 12) software.
NMR has also been used in recent years for direct performance indicating analysis of excipients through imaging. One example is the swelling and erosion of extended release matrixes such as the HPMC tablet matrix shown in Figure 1.8. This type of functional test can distinguish attributes relevant to the release mechanism(s) such as gel layer thickness and density, which impact the selection of the tablet excipients. Here a round HPMC matrix tablet containing a weakly basic drug and an acid-modifying excipient demonstrates a consistent and faster disappearance of the dry core when exposed to an aqueous neutral buffer solution. The dry tablet core is shown in dark contrast and the hydrated HPMC gel layer is resolved in lighter (white/grey) area surrounding the core. The rate of disappearance of the dry tablet core can be analyzed by integrating the area of the dark core in these images and plotting the time course (bottom plot in Figure 1.8). At all time points, the HPMC matrix with the acid-modifying excipient had a lower dry core area and this difference became more pronounced at later time points. This method allows dynamic measurement of the contribution of erosion and diffusion of drug through an HPMC polymer matrix to rationally design the target release rate. In addition, it is possible to design more elaborate methods that can also capture chemical information by quantification of elements of interest such as 19F, 35Cl, and 31P contained in numerous excipients (e.g., impact of residual salts or degree of phosphate cross-linking in super disintegrant swelling kinetics) or to track the diffusion of a labeled drug substance.
Figure 1.8 (a) Low-field NMR analysis of HPMC matrix tablets providing time course images of the darker dry tablet core and lighter gel layer in a static aqueous buffer solution (SEMS, Tr = 1800 ms, NS = 2, Te = 6 ms) and (b) corresponding area of the dry tablet core over 8 hours in aqueous media.
Images courtesy of Sarah Hanley and Jonathan Brown (Bristol-Myers Squibb, 2012).
1.4.3 Atomic Force Microscopy
Atomic force microscopy (AFM) cantilevers can be functionalized with excipients or drug particles and used as probes to investigate the effect of surface chemistry on the interaction with another material in a drug product. Functionalized AFM probe tips can be constructed to provide a localized solid–solid interface between pharmaceutically relevant materials. This microscopic interface provides for high-resolution contact that can identify specific physical and chemical interactions such as studying solid-state decomposition reactions between excipients and drug substances. The use of a force–displacement mode also provides direct quantification of adhesion forces from controlled interactions between two material surfaces.
An example of a novel AFM technique was recently published where the authors determined the impact of dicalcium phosphate dihydrate (DCP) toward the solid-state hydrolysis of aspirin [16]. In this study, the anisotropic surface chemistry of the crystals, which present different reactive functional groups on various crystal faces, were determined to contribute to the reactivity of aspirin in contact with DCP. A strong interaction was identified between DCP and the aspirin (100) surface at 75% RH leading to formation of local pits. These pits were also associated with formation of needle shaped crystals normal to the surface in Figure 1.9a and hypothesized (absent chemical data) to be consistent with the growth of crystalline salicylic acid due to aspirin hydrolysis. Furthermore, the interaction was highly dependent on the formation of a water layer on the aspirin (100) surface above 40% RH marked by a significant shift in the force-displacement profile (Figure 1.9b) resulting from chemical, electrostatic, and meniscus contributions. This elegant study demonstrates how highly specific tests involving unique design elements such as probe tip fabrication can greatly advance the fundamental understanding of material properties and the solid-state reactivity of excipients. This type of characterization does require highly experienced analysts for the diligent conduct and analysis of detailed data sets, which can limit routine use in development programs. However, AFM is well suited to addressing complex chemical and physical behaviors in a wide variety of pharmaceutical systems.
Figure 1.9 AFM measurements of dicalcium phosphate dihydrate in contact with aspirin (100) surface (a) image 30 minutes after contact demonstrating pits and new crystalline grown on aspirin surface and (b) and (c) force–displacement curves for low and high RH condition, respectively.
Source: Cassidy [16]. Reproduced with permission of Elsevier.
1.4.4 Process Analytical Technologies (PAT)
Many established analytical measurement systems are being utilized with novel integration strategies to provide real-time data on pharmaceutical processing of drug product intermediates and excipients. These efforts have been encouraged by global regulatory agencies and the pharmaceutical industry to monitor and control critical process parameters that are linked to important performance and material attributes. Excipients are widely used to impart function and/or processability to drug products and are therefore critical components of any effort to monitor drug processes in real time. Extensive process analytical technology (PAT) examples and reviews are available in the literature and also described in more detail in Chapter 9, which demonstrates the combined efforts to increase the use throughout development and commercial manufacture. A simple examination of the literature demonstrates a large increase for the number of publications focused on PAT in the last decade as shown in Figure 1.10. A strong focus in this area by regulators, academic institutions, and the pharmaceutical industry is also apparent in a listing of top contributors from US institutions.
Figure 1.10 Number of documents containing the keyword process analytical technology in pharmacy and engineering journals between 1980 and 2014 in Scopus database. The number of documents per year is indicated in (a) and the top contributing US institutions are listed in (b).
One representative example of PAT implementation is for the fluid bed drying of ibuprofen granulation. In this study, NIR was utilized to directly provide a continuous measurement of moisture content for the drug product intermediate [8b]. Since most drug products have chemical and physical stability that is sensitive to temperature and moisture content during processing, it is critical to monitor and optimize drying conditions and parameters. Therefore, the propensity of excipients to sequester moisture and the associated thermodynamics and kinetics of moisture transfer is important to determine when screening formulations and processes. Excipients that provide strong associations with water (bound water) can lead to formulations with a dominant diffuse phase of drying and very small evaporative phases. This type of excipient behavior can cause lengthy drying processes and a predominant exponential region of the drying curve. However, excipients and formulations with linear evaporative cooling behavior are amenable to accelerated drying conditions. This behavior is shown for ibuprofen–starch granulation in Figure 1.11 where fast drying was suitable to achieve an approximately 50% time reduction over the normal process. This type of advanced analytical monitoring facilitates a mechanistic understanding of the drying process and identification of any excipient or material constraints to assure high-quality robust operation parameters are selected.
Figure 1.11 Fluid bed drying curves for ibuprofen granulation monitored by in-line NIR measurement of the moisture content.
Source: Wildfong [8b]. Reproduced with permission of Elsevier.
1.5 Excipient Impurities and Implications to Drug Product Stability (Drug–Excipient Interactions)
Pharmaceutical excipients have been studied extensively to obtain a detailed understanding of the properties and functionalities they exhibit in solid dosage formulations. Excipients can play different functions in a formulation, such as: to attribute proper mechanical property for a formulation to enhance drug product manufacturability; to ensure drug product performance by governing the mode and rate of drug release from a dosage form for immediate or extended drug delivery; or to improve drug product stability.
Excipients and impurities contain reactive functional groups. A survey of current literature indicates that the majority of the drug product stability issues are due to interactions of drugs with excipients and/or reactive impurities contained in the excipients (Table 1.4). Impurities are introduced into excipients as residues from the manufacturing process and raw materials or as degradants from excipient aging. Even though the
